| Ytd | -0.96% | |
| 1y | 31.85% |
| Open | 79.19 | Prev Close | 80.03 | Low | 77.51 | High | 80.53 | Mkt Cap | 3.02B |
| Vol | 882.04K | Avg Vol | 524.62K | EPS | -6.59 | P/E | N/A | Forward P/E | -10.83 |
| Beta | 2.06 | Short Ratio | 22.19 | Inst. Own | 114.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 76.86 | 200-d Avg | 74.29 | 1yr Est | 101.58 |
IRON News
NEW YORK, Aug. 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
Disc Medicine, Inc. (NASDAQ: IRON - Get Free Report) has been assigned an average recommendation of
NEW YORK, Aug. 26, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
New York, New York--(Newsfile Corp. - August 24, 2026) - WHY: Rosen Law Firm, a global investor righ
New York, New York--(Newsfile Corp. - August 23, 2026) - WHY: Rosen Law Firm, a global investor righ
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Inv
NEW YORK, Aug. 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, cont
NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Inv
NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, cont
NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
New name and symbol mark the Company's transformation into a focused, near-term iron developer — anc
New York, New York--(Newsfile Corp. - August 9, 2026) - WHY: Rosen Law Firm, a global investor right
New York, New York--(Newsfile Corp. - August 8, 2026) - WHY: Rosen Law Firm, a global investor right
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, conti
HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
New York, New York--(Newsfile Corp. - August 2, 2026) - WHY: Rosen Law Firm, a global investor right
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.54) per share which beat the analyst co
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and m
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove
Consistent, substantial decreases in hepcidin reaching >75% reduction from baseline and correspon
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and ra
https://subscriber.politicopro.com/article/2026/05/makarys-time-atop-fda-over-tktk-named-acting-comm
https://www.cbsnews.com/news/trump-approves-plan-to-fire-fda-commissioner-marty-makary/?intcid=CNM-0
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.65) per share which beat the analyst co
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discove
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and rai
On February 26, 2026, the board of directors of Disc Medicine, Inc. (the "Company") approved
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and low
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.62) per share which beat the analyst co
Stifel analyst Stephen Willey maintains Disc Medicine (NASDAQ:IRON) with a Buy and lowers the pri
Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight
BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ:IRON) with a Outperform and lo
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and low
Disc Medicine stock plunged after an FDA rejection of its rare disease drug but rebounded as investo
Disc Medicine, Inc. (NASDAQ:IRON), a biopharmaceutical company focused on the discovery, development
The FDA delays its decision on Disc Medicine's rare disease drug bitopertin, raising review ques
FDA delayed fast-track reviews for multiple drugs after safety and efficacy concerns, including adve
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and rai
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baselin
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and rai
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.77) per share which missed the analyst